There have been a number of studies of the effect of chlorpromazine on REM sleep and also studies of REM deprivation in normal subjects and in those with various psychiatric syndromes; in several of these studies the patients were on medication. But there has been no previous study of the effect of chlorpromazine on rebound from REM deprivation in normal subjects.
Introduction
There have been a number of studies of the effect of chlorpromazine on REM sleep and also studies of REM deprivation in normal subjects and in those with various psychiatric syndromes; in several of these studies the patients were on medication. But there has been no previous study of the effect of chlorpromazine on rebound from REM deprivation in normal subjects.
The existence of REM rebound in normal subjects was demonstrated in Dement's classical studies (2, 3) , but the effect of deprivation and the degree of rebound in psychiatric patients has remained controversial.
Zarcone and Dement (14) compared the response to REM deprivation of acutely psychotic schizophrenics and of schizophrenics in remission who were on medication. These authors reported that schizophrenics in remission had an exaggerated rebound, while hallucinating and delusional schizophrenics had little or none. They concluded that failure to confine the events of the REM period to that period, (that is, an unrestricted release of these internally generated discharges in the waking state) could be the basis for the development of many manifestations of schizophrenic psychosis. Feinberg (5) recommended caution regarding Zarcone and Dement's interpretation of the lack of a compensatory REM rebound. He noted that their patients were presumably extremely anxious and he advised the study of a group of extremely anxious but non-psychotic subjects. He also noted that the patients studied were receiving therapeutic doses of tranquillizing medication, and that the effects of these drugs on the patients' deprivation response might differ according to the clinical state. ' The effect of phenothiazines on REM time (but not on rebound from REM deprivation) has been described in a number of studies. Feinberg noted a decrease in REM time in schizophrenic patients but indicated that after single large doses of phenothiazines there were cases involving long sleep latency and stage 1 sleep onset accompanied by occasional REMs (4). Sagales et al. (12) , using doses of 50 to 100 mg. of ch.orpromazine, did not confirm the effect on REM time. Hartmann (7) found no effect of chlorpromazine on the distribution of sleep stages. Lester (9) reported an increase in REM time and a decreased latency in normal subjects who were receiving 100 mg. of chlorpromazine at bedtime. The increase in total REM time was not significant but that in the first REM period was. Toyoda (13) reported an increase in REM time with 50 mg. of chlorpromazine at bedtime in two neurotic subjects. Lewis and Evans (10) showed that 25 mg. of chlorpromazine increase REM time while 100 mg. decrease it, and they tried to explain their results on the basis of the difference in the doses used.
The aim of this study was to examine the variable of medication in its effects on rebound from REM deprivation in a group of normal subjects. The design was also intended to explore the stability of the rebound effect under conditions of repetition of REM deprivation in the same subject.
Method
Six subjects came to sleep in the laboratory. They were 'normal' in that they had no history of psychiatric illness or treatment. Informed consent was obtained in all cases, and the participants were paid $10 for each night spent in the laboratory.
The subjects came to the laboratory approximately one hour before their usual bedtime. An EEG recording was made, using a Beckman TD apparatus. Beckman electrodes were applied with collodion. The eye electrodes were applied, using surgical eye tape. The positions used were the following: C4 -A2, CZ -FZ, FZ -PZ. The eye electrodes were paired with A2 and an additional channel recorded differences in potential between the eyes. The EMG was recorded with two submental electrodes.
The experiment consisted of three periods of nine nights each. A baseline was established during a period of three nights, and this was followed by two nights of REM deprivation and four recovery nights during which the rebound could be observed. REM deprivation was accomplished by awakening the subject by means of a buzzer and by calling out his name when the onset of the REM stage was observed on the EEG tracing.
The first ten-day period was without medication. After about a week, the second period of the experiment started and during this the subjects took chlorpromazine in the dosage of approximately 1 mg.lkg. at bedtime -see Table I .
This dose level at bedtime was constant unless difficulties arose.
The third ten-day period was again without medication, and it followed the second period by approximately three weeks. The effect of the withdrawal of medication on sleep was not studied but none of the subjects reported any major difficulties. The EEG recordings were scored by one of the authors, according to the method of Rechtschaffen and Kales (11); interrater agreement of better than 90 per cent was established.
Results
Results were obtained from five of the subjects; the sixth, a twenty-one year old student and actress, had to withdraw from the experiment because of side effects which included dizziness, weakness and systolic blood pressure below 90. Table II and Graph 1 show the means of the measurements under the three sleep conditions (baseline, REM deprivation and recovery) in four dependent variables: total sleep time in minutes (TST), REM time in minutes (REM), latency of the first REM period in minutes (LT) and REM time expressed in percentage of the total sleep time (REM per cent). Table II shows the values before medication, during the administration of medication and after medication. Table III contains the results of the analysis of variances (three-way classification) which was computed in order to evaluate the main effects as well as the interactions between the medication and sleep conditions. The computational design took into account the effects of replication of the measurements over time in the same subjects.
The results concerning the main effects (simple contrasts) indicate a significant difference over the three conditions of sleep (baseline, REM deprivation and recovery). The F's were highly significant in all variables except the L T, and range from F = 15.18 to 162.36, df = 2/8, P < 0.01.
Comparison of the baseline and recovery REM times (before, during and after medication) approached but fell short of significance. The F-values ranged from 0.69 to The results showed no interaction effects between medication and the sleep condition or between medication and replication in the examined subjects. The F's ranged from 0.44 to 1.04 and fell short of significance in all of the variables.
In addition it was found that the pharmacological effect of chlorpromazine on these normal subjects varied.' Subjects 1 and 2 were not markedly inconvenienced and continued their work as students but complained of a slight difficulty in concentration, which was perhaps related to drowsiness. Subject 5 also complained of this. Subject 6, who had to withdraw from the experiment while under medication, had more marked side effects, as did the two remaining subjects. These difficulties were mostly autonomic nervous system symptoms (hypotension, nausea, tachycardia and dizziness) which interfered with their activities.
Subject No.4 was a young, single woman who in the past had worked as a nurse. The reason for her leaving her position was not known. Her participation in the experiment was strongly motivated by financial need and she mentioned difficulties in finding employment. She was worried by acneiform lesions and was under the care of a dermatologist. She had a special diet which she could not follow for financial reasons. When placed on medication (125 mg. of chlorpromazine during the day and 50 mg. one hour before bedtime) she began to have orthostatic hypotension in the morning, was dizzy and nauseated and became afraid of having to withdraw from the experiment. The daytime medication was reduced to 75 mg. but to no avail, so that this was then discontinued but the night-time medication remained unchanged. During the second recovery night 
Discussion
The results show that there was no significant difference between REM rebound with and without medication.
While there can be no certainty that the effect of chlorpromazine on normal subjects in an experimental situation and on patients who are given the medication for therapeutic purposes is identical, these findings do suggest that REM deprivation in patients who are receiving medication is not significantly affected by the medication.
The purpose of the third ten-day period was twofold: to see whether increased familiarity with the laboratory surroundings would affect the results; and whether there was any lingering effect of chlorpromazine due to slow excretion ( 1). It has since been shown that the action of chlorpromazine is related to plasma concentration and that the latter becomes minimal after 72 hours (6) .
Thus, the three recovery responses are similar except that with medication some features appear which will now be discussed. Although the hypnotic effect was not measured as such, the subjects taking chlorpromazine fell asleep more rapidly. The increase in Total Sleep Time was not significant during the baseline days preceding deprivation. The slight hypnotic effect did not seem to decrease, as reported by Kupfer (8) . The premature REM noted by Feinberg was not observed in this study except that one subject, following deprivation, had a REM period seven minutes after falling asleep.
The results concerning increased variability of standard deviations of the REM time in subjects under medication could be due to -either variability in side effects or to anxiety factors.
Under the influence of chlorpromazine the standard deviation of the REM time decreased from 21.96 to 18.03 for the baseline but increased from 8.43 to 11.37 for the nights of deprivation and from 14.08 to 21.24 for the nights of recovery (rebound). it took her one and a half hours to fall asleep. Her TST became shorter and the REM time decreased to 19.1 per cent. Subject No.2 was a 26 year-old married man who worked as manager in a movie theatre. His mental state seemed normal at first but while taking the medication he began to complain of difficulties at work and of psychological symptoms. He felt that his head was heavy, he had difficulty concentrating, began to neglect his work and worried about the effects of the medication. On the day preceding the second deprivation night the daytime medication was reduced by 25 mg. On the day preceding the second recovery night he had an episode of tachycardia and he became concerned about the possible dangers. He was reassured and came to the laboratory as usual. However, even though his TST did not decrease appreciably his REM percentage showed a marked decrease, as had that of the fourth subject. That night was also followed by a greater recovery, as shown on Graph 2. The recovery curves of the subjects under medication were different. It seems possible that there were two groups of reactors to medication here. Perhaps the plasma levels of different subjects vary because of different rates of metabolic breakdown.
The results of the study reported here suggest that the findings of Zarcone and Dement (14) cannot be accounted for as heing due to medication.
Summary
The effect of chlorpromazine on the REM deprivation rebound was studied. Five normal subjects participated in the experiment which consisted of three periods of nine nights each. The first period was without medication, the second with medication and the third again without medication. Four dependent variables -Total Sleep Time, REM latency, REM time and REM percentage~were measured in each period as follows: baseline -three nights, REM deprivation -two nights and recoveryfour nights.
Analysis of variance (three-way classification) was computed in order to evaluate both the main effects as well as the interaction between medication and sleep conditions. The results showed significant difference over the three conditions of sleepbaseline, REM deprivation and recovery. While there were no significant differences due to medication the replication of the measurements in the same subjects proved to be a slightly significant source of the variance of the scores in all variables except REM latency.
Resume
Cette recherche avait pour but d'etudier l'effect de la chlorpromazine sur Ie "REM rebound". L'experience menee avec cinq sujets normaux, comprenait trois periodes de neuf nuits chacune. A la premiere periode aucune medication n'etait administree, la seconde periode etait sous medication et enfin, la troisierne etait une periode sans medication a nouveau. Quatre variables dependantes (temps total de sommeil, latence REM, temps REM et pourcentage REM) ont ete mesurees a chaque periode comme suit: ligne basale -3 nuits, privation de REM -2 nuits et recuperation -4 nuits. L'analyse de la variance (trois manieres de classification) a ete effectuee afin d'evaluer des principaux effects, des medications et des conditions de sommeil ainsi que l'interaction entre les deux. Les resultats indiquent une difference significative dans les 3 conditions de sommeil (ligne basale, priva-tion de REM et recuperation). Alors qu'il n'y a aucune difference significative due a la medication, une repetition des mesures avec les meme sujets montre une legere source significative de la variance des scores pour toutes les variables sauf pour la latence REM. 
